This qualification is the first time a regulatory body has formally supported a machine learning-based method for reducing sample size in Phase II or III trials.
What's new ?
top of page
Pharma Nuclear Services
Search
bottom of page
Pharma Nuclear Services
This qualification is the first time a regulatory body has formally supported a machine learning-based method for reducing sample size in Phase II or III trials.
Comments